Add Formweb to your mobile device
Search results for:
tarlatamab
tarlatamab
Brand names: Imdelltra
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 1mg or 10mg; dlle 1 mg; dlle 10 mg | NON FORMULARY |
Last updated: Aug. 28, 2025
Tarlatamab should only be administered in a facility with appropriate medical support and by providers experienced in managing severe reactions such as CRS and neurotoxicity, including immune effector cell–associated neurotoxicity syndrome (ICANS). Monitor patients in an appropriate health care setting during infusion and for 22 to 24 hours after the cycle 1 day 1 and cycle 1 day 8 infusions; patients should remain within 1 hour of an appropriate facility and be accompanied by a caregiver for a total of 48 hours from the beginning of the cycle 1 day 1 and cycle 1 day 8 infusions.